A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Renal insufficiency may increase the risk of hypoglycemia in hospitalized patients with diabetes who are treated with insulin. We randomized inpatients with type 2 diabetes and chronic renal failure to treatment with two different dose levels of insulin glargine and glulisine and studied control of hyperglycemia and the frequency of hypoglycemia. RESEARCH DESIGN AND METHODS: We conducted a multicenter, prospective, randomized trial to compare the efficacy of once-daily glargine and three-times daily glulisine at 0.5 vs. 0.25 units/kg/day. A total of 107 subjects had type 2 diabetes for >1 year, had a glomerular filtration rate <45 mL/min but did not require dialysis, and had an initial blood glucose (BG) >180 mg/dL. Doses were adjusted based on four-times daily BG measurements for 6 days. RESULTS: Mean BG on the first day was 196 ± 71 mg/dL in the group receiving 0.5 units/kg (0.5 group) and 197 ± 55 mg/dL in the group receiving 0.25 units/kg (0.25 group; P = 0.94). On days 2 to 6, mean BG was 174 ± 52 mg/dL in the 0.5 group and 174 ± 46 mg/dL in the 0.25 group (P = 0.96). There were no significant differences between groups in the percentage of BG values within the target range of 100 to 180 mg/dL on any of the 6 study days. In the 0.5 group, 30% experienced hypoglycemia (BG <70 mg/dL) compared with 15.8% of the 0.25 group (P = 0.08). CONCLUSIONS: Reduction of initial glargine/glulisine insulin weight-based dosing in hospitalized patients with diabetes and renal insufficiency reduced the frequency of hypoglycemia by 50% without compromising the control of hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Persons without DM but with stress or newly diagnosed hyperglycemia who have required an insulin rate less than 1 to 2 units/hour at the time of transition may not require a scheduled subcutaneous insulin regimen.1330”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1330]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266
Umpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Economic Costs of Diabetes in the U.S. in 2007
Leahy, J. L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79219-9 · Cited by 781
Umpierrez, G. E., Smiley, D., Jacobs, S., Peng, L., Temponi, A., Mulligan, P., Umpierrez, D., Newton, C., Olson, D., & Rizzo, M. (2011) · Diabetes Care · doi:10.2337/dc10-1407 · Cited by 720
Umpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., & Mejia, R. (2007) · Diabetes Care · doi:10.2337/dc07-0295 · Cited by 671
Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward
Turchin, A., Matheny, M. E., Shubina, M., Scanlon, J. V., Greenwood, B., & Pendergrass, M. L. (2009) · Diabetes Care · doi:10.2337/dc08-2127 · Cited by 453
Frequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423 · cited 1×
“Patients with diabetes and renal insufficiency present a greater challenge because of their increased risk for hypoglycemia, especially when the GFR is ,60 mL/min (21).”
Background
Research works printed but not linked: 1
- 20. Fadda GZ Massry SG Metabolic and endocrine disturbances in uremia: glucose and insulin metabolism. In Textbook of Nephrology. Massry SG Glassock RJ, Eds. Hagerstown, MD, Williams & Wilkins, 1998, p. 1390– 1395
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“Typical dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses (474).”
BackgroundUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia
Umpierrez, G., & Korytkowski, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.15 · Cited by 563
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s016 · Cited by 440
“Typically, basal insulin dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses (60,61).”
Background15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s015 · Cited by 265
15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s015 · Cited by 216
“Typically, basal insulin dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses (41).”
Background16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s016 · Cited by 195
16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s016 · Cited by 221
15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s015 · Cited by 197
16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Galindo, R. J., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s016 · Cited by 167
14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s014 · Cited by 178
Interactions between kidney disease and diabetes: dangerous liaisons
Pecoits-Filho, R., Abensur, H., Betônico, C. C. R., Machado, A. D., Parente, E. B., Queiroz, M., Salles, J. E. N., Titan, S., & Vencio, S. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 171
Pasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30402-8 · Cited by 168
Insulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 153
Self-citationInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Management of diabetes mellitus in patients with chronic kidney disease
Hahr, A. J., & Molitch, M. E. (2015) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-015-0001-9 · Cited by 142
“25 units/kg showed similar glycemic control but significantly less hypoglycemia in the group with the lower weight-based dose [25].”
BackgroundSelf-citationImpaired Glucose and Insulin Homeostasis in Moderate-Severe CKD
de Boer, I. H., Zelnick, L., Afkarian, M., Ayers, E., Curtin, L., Himmelfarb, J., Ikizler, T. A., Kahn, S. E., Kestenbaum, B., & Utzschneider, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015070756 · Cited by 106
Perioperative management of hyperglycemia and diabetes in cardiac surgery patients
Galindo, R. J., Fayfman, M., & Umpierrez, G. E. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.005 · Cited by 95
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
“Reduction of initial glargine/glulisine insulin weight-based dosing in hospitalized patients with T2DM and RI reduced the frequency of hypoglycemia by 50% without compromising the control of hyperglycemia [162].”
Background14. Diabetes Care in the Hospital
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s017 · Cited by 110
“dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses (25).”
BackgroundA Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic
Korytkowski, M., Antinori-Lent, K., Drincic, A., Hirsch, I. B., McDonnell, M. E., Rushakoff, R., & Muniyappa, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa342 · Cited by 89
“Patients with preexisting chronic kidney disease or who experience acute kidney injury as part of COVID-19 infection may be particularly sensitive to insulin and risk for hypoglycemia (30-32).”
Background13. Diabetes Care in the Hospital
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s016 · Cited by 103
“Typically basal insulin dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses (15).”
BackgroundGlycemic Management in ESRD and Earlier Stages of CKD
Williams, M. E., & Garg, R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.049 · Cited by 101
Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0113-2 · Cited by 75
Betônico, C. D. C. R., Titan, S., Corrêa‐Giannella, M. L., Nery, M., & Queiroz, M. S. (2016) · Clinics · doi:10.6061/clinics/2016(01)08 · Cited by 88
“However, one study that enrolled hospitalized patients with the objective of evaluating insulin doses and hypoglycemia frequency showed that after initial reduction of glargine/glulisine insulin weight-based dosing, there was a notable decline in hypoglycemic events, or a 50% reduction, without compromising glycemic c…”
BackgroundRahhal, M.-N., Gharaibeh, N. E., Rahimi, L., & Ismail‐Beigi, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00286 · Cited by 68
13. Diabetes Care in the Hospital, Nursing Home, and Skilled Nursing Facility
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s016 · Cited by 66
“Typical dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses (18).”
Hyperglycemia and Acute Kidney Injury During the Perioperative Period
Mendez, C. E., Mesropian, P. J. D., Mathew, R. O., & Slawski, B. A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0701-7 · Cited by 59
Neubauer, K. M., Mader, J. K., Höll, B., Aberer, F., Donsa, K., Augustin, T., Schaupp, L., Spat, S., Beck, P., Fruhwald, F. M., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0027 · Cited by 51
“60 Diet only 3 (3) 0 (0) 1 (3) 2 (5) 0 (0) OAD only 16 (16) 0 (0) 6 (20) 8 (19) 2 (17) Insulin only 55 (56) 12 (80) 13 (44) 24 (58) 6 (50) OAD, GLP-1 analogs 1 (1) 0 (0) 0 (0) 1 (2) 0 (0) Insulin, OAD 22 (22) 3 (20) 9 (30) 6 (14) 4 (33) Insulin, GLP-1 analogs 2 (2) 0 (0) 1 (3) 1 (2) 0 (0)”
Lee, Y.-Y., Lin, Y.-M., Leu, W.-J., Wu, M.-Y., Tseng, J.-H., Hsu, M.-T., Tsai, C.-S., Hsieh, A.-T., & Tam, K.-W. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.011 · Cited by 51
Diabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
Self-citationPharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
Mendez, C. E., & Umpierrez, G. E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.3.180 · Cited by 46
Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease
Gosmanov, A. R., Gosmanova, E. O., & Kovesdy, C. P. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv258 · Cited by 48
“25 u/kg/day was safe and effective in themanagement of diabetes in acute setting [25].”
BackgroundBaldwin, D., & Apel, J. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0339-7 · Cited by 41
Self-citationHyperglycemia and Diabetes Mellitus Following Organ Transplantation
Galindo, R. J., & Wallia, A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0707-1 · Cited by 39
Hypoglycemia in Hospitalized Hemodialysis Patients With Diabetes: An Observational Study
Gianchandani, R. Y., Neupane, S., & Heung, M. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817747620 · Cited by 40
Mader, J. K., Neubauer, K. M., Schaupp, L., Augustin, T., Beck, P., Spat, S., Höll, B., Treiber, G. M., Fruhwald, F. M., Pieber, T. R., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12186 · Cited by 36
“A recent study of two different weight-based dose levels of a basal–bolus regimen in hospitalized patients with diabetes and impaired kidney function showed that a lower insulin dosing reduced the frequency of hypoglycaemia by 50% without compromising the control of hyperglycaemia [21].”
BackgroundRoussel, R., Lorraine, J., Rodríguez, Á., & Salaun-Martin, C. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0261-x · Cited by 38
“lower risk of hypoglycemia and no loss of hyperglycemic control in a randomized controlled trial [174].”
BackgroundDiabetes Management in the Kidney Patient
Garg, R., & Williams, M. E. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.11.001 · Cited by 34
“A study in hospitalized patients suggested that insulin dose may be reduced by approximately 50% in CKD.(105) Effects of dialysis on insulin sensitivity can further complicate insulin therapy in patients with ESRD.”
BackgroundConsensus statement on insulin therapy in chronic kidney disease
Rajput, R., Sinha, B., Majumdar, S., Shunmugavelu, M., & Bajaj, S. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.032 · Cited by 33
Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis
Iyengar, R., Franzese, J., & Gianchandani, R. Y. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1044-y · Cited by 31
Haak, T., Fritsche, A., Füchtenbusch, M., Gehr, B., Gölz, S., Kröger, J., Siegmund, T., Ziegler, R., Droßel, D., Fuchs, S., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0984-5696 · Cited by 29
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 32
Inpatient Diabetes Management in the Twenty-First Century
Khazai, N. B., & Hamdy, O. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.013 · Cited by 32
Blaine, E., Tumlinson, R., Colvin, M., HAYNES, T. G., & Whitley, H. P. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2659 · Cited by 26
Rubin, D. J., & Golden, S. H. (2013) · Hospital Practice · doi:10.3810/hp.2013.02.1016 · Cited by 28
Management of Post-Transplant Diabetes
Therasse, A., Wallia, A., & Molitch, M. E. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0346-8 · Cited by 27
Self-citationGalindo, R. J., Davis, G. M., Fayfman, M., Reyes-Umpierrez, D., Alfa, D., Peng, L., Tamler, R., Pasquel, F. J., & Umpierrez, G. E. (2017) · Endocrine Practice · doi:10.4158/ep171804.or · Cited by 21
Adverse safety events in patients with Chronic Kidney Disease (CKD)
Offurum, A. I., Wagner, L.-A., & Gooden, T. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1236909 · Cited by 23
“without compromising hyperglycemia control [55].”
Safe and Appropriate Use of Insulin and Other Antihyperglycemic Agents in Hospital
Cornish, W. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.002 · Cited by 20
A Systematic Approach for the Prevention and Reduction of Hypoglycemia in Hospitalized Patients
Cruz, P., Blackburn, M. C., & Tobin, G. S. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0934-8 · Cited by 20
Current therapeutic approaches in the management of hyperglycemia in chronic renal disease
Garla, V. V., Yanes-Cardozo, L. L., & Lien, L. F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9416-1 · Cited by 19
“25 units/kg/day [80] & Patients with Type 2 diabetes mellitus and ESRD on hemodialysis may only need once-daily morning doses of basal insulin (rather than twice daily basal insulin regimens) & Patients with Type 1 diabetes mellitus and ESRD on hemodialysis (who may still benefit from twice daily basal insulin doses)…”
BackgroundSandler, V., Misiasz, M. R., Jones, J. D., & Baldwin, D. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814540870 · Cited by 16
“In addition, we focused on BG control in the subpopulation of patients with chronic renal failure since our previous work has shown their increased risk of hypoglycemia during treatment with insulin.(13)”
BackgroundSelf-citationGosmanov, A. R. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.05.002 · Cited by 19
“5 units/kg/day [52].”
Glycemic Management in Medical and Surgical Patients in the Non-ICU Setting
Hawkins, K., Donihi, A. C., & Korytkowski, M. T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0340-1 · Cited by 17
New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences
Popović, L., & Bulum, T. (2025) · Diagnostics · doi:10.3390/diagnostics15030284 · Cited by 17
“…significantly fewer hypoglycemic episodes than those receiving 0.5 units/kg. immunosuppres-sants (except saxagliptin) (GLP-1) receptor - weight loss Insulin-treated patients must closely monitor their blood glucose levels and adjust the doses to mitigate the risk of hypoglycemia [64,93].”
InfluentialRole of the Diabetes Educator in Inpatient Diabetes Management
(2017) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721716683813 · Cited by 10
“• empowering patients and caregivers to actively participate in their care(14,17); • providing a clear and feasible management plan at discharge based on clinical needs, patient preferences, goals, and abilities(14,16,17,33); • ensuring that a follow-up appointment for diabetes care is scheduled prior to discharge(17,…”
BackgroundInpatient Use of Computer-Guided Insulin Devices Moving into the Non–Intensive Care Unit Setting
Gianchandani, R. Y., & Umpierrez, G. E. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0213 · Cited by 10
“5 units/kg/day, depending on the renal function of patients.(2,3,13) Normal basal bolus ratios are approximately 50% basal and 50% bolus, with bolus doses further divided somewhat equally among three meals.”
BackgroundMajumder, A., RoyChaudhuri, S., & Sanyal, D. (2019) · Cureus · doi:10.7759/cureus.6191 · Cited by 9
Bajwa, S. J., Sehgal, V., Khaira, U., Sehgal, R., & Bajaj, A. (2013) · Journal of the Scientific Society · doi:10.4103/0974-5009.120052 · Cited by 10
Role of the Diabetes Educator in Inpatient Diabetes Management
American Association of Diabetes Educators (2018) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721718754817 · Cited by 10
Sáenz-Abad, D., Gimeno-Orna, J. A., Sierra-Bergua, B., Lahoza-Pérez, M. C., & Pérez‐Calvo, J. I. (2015) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272015000300004 · Cited by 7
D’Netto, M. E., Murphy, C. V., Mitchell, A., & Dungan, K. M. (2015) · Hospital Practice · doi:10.1080/21548331.2016.1130584 · Cited by 6
Role of the Diabetes Educator in Inpatient Diabetes Management
American Association of Diabetes Educators (2018) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721718820944 · Cited by 5
The clinical impact of hypoglycemia in hospitalized patients
Borzì, V., & Fontanella, A. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.2015.549 · Cited by 6
Therapie des Typ-1-Diabetes: Kurzfassung der S3-Leitlinie. Version 5.0, AWMF-Registernummer: 057-013
Haak, T., Fritsche, A., Füchtenbusch, M., Gehr, B., Gölz, S., Kröger, J., Siegmund, T., Ziegler, R., Droßel, D., Fuchs, S., et al. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0276 · Cited by 6
In-Silico Trials for Glucose Control in Hospitalized Patients with Type 2 Diabetes
Choi, K., Oh, T. J., Lee, J. C., Kim, M.-J., Kim, H. C., Cho, Y. M., & Kim, S. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.2.231 · Cited by 5
“��� �� ��� � ���� ������� � ����� � ������� � ���� (9)”
BackgroundResultInfluentialManagement of Hyperglycemia in Hospitalized Noncritical Patients
Mikhail, N. E. (2013) · Southern Medical Journal · doi:10.1097/smj.0b013e318287febe · Cited by 3
“8%, respectively.(23) Therefore, insulin doses should be decreased by 50% in patients with moderate and severe renal failure to avoid hypoglycemia (Table 4).”
BackgroundTubular Secretory Clearance Is Associated With Whole-Body Insulin Clearance
Huber, M. P., Zelnick, L. R., Utzschneider, K. M., Kahn, S. E., de Boer, I. H., & Kestenbaum, B. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa522 · Cited by 4
Antidiabetic Therapy in End‐Stage Renal Disease
Boyle, S. M., Simon, B. F., & KOBRIN, S. M. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12368 · Cited by 4
“There is no clear superiority of one approach versus another, so rapid-acting agents are sometimes used for their convenient advantage of being able to be administered immediately before a meal as opposed to 30–45 minutes prior to a meal, as is the case with regular insulin (57,58).”
BackgroundMallappallil, M. C., Sasidharan, S., Sabu, J., & John, S. (2024) · Cureus · doi:10.7759/cureus.64663 · Cited by 3
“There is no clear directive for the use of long-acting insulins for patients on dialysis, either HD or PD. Long-acting insulin may require a dose reduction to avoid hypoglycemia [38].”
BackgroundInfluentialPerioperatives Management von Menschen mit Diabetes mellitus: Diabetologie
Lehmann, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01366-2 · Cited by 2
Therapie des Typ-1-Diabetes: Kurzfassung der S3-Leitlinie. Version 5.0, AWMF-Registernummer: 057-013
Haak, T., Fritsche, A., Füchtenbusch, M., Gehr, B., Gölz, S., Kröger, J., Siegmund, T., Ziegler, R., Droßel, D., Fuchs, S., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-7826 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Passarella, P., & Gosmanov, A. R. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.001 · Cited by 1
Camuto, P., Guadagnini, D., Assalin, H. B., Magro, D. O., Santos, A., & Saad, M. J. A. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.06.010 · Cited by 1
Umpierrez, G. E., Orobio, C., Petty, K. B., Nalabolu, S., Oladejo, O., & Vellanki, P. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006596 · Cited by 1
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Klimontov, V. V., & Мякина, Н. Е. (2014) · Diabetes Mellitus · doi:10.14341/dm2014499-107 · Cited by 1
Management of Diabetes and/or Hyperglycemia in Hospitalized Patients with Renal Insufficiency
Matfin, G. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch37 · Cited by 1
Managing Diabetes in Patients Hospitalized in Internal Medicine Units
Hochberg, I. (2018) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10334 · Cited by 1
Inpatient Management of Type 2 Diabetes Mellitus
Lee, H. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-84367-0_41 · Cited by 1
Self-citationInpatient Management of Patients with Diabetes and Kidney Disease
Patel, E., Kim, S. H., & Gianchandani, R. Y. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_23 · Cited by 2
Principles of Care in the Diabetic Surgical Patient
Khazai, N. B., & Hamdy, O. (2024) · Contemporary diabetes · doi:10.1007/978-3-031-55715-6_6 · Cited by 1
Feng, Q., Li, B., Lin, J., Zou, L., Xu, W., Zeng, L., Li, P., & Lin, S. (2025) · International Journal of Endocrinology · doi:10.1155/ije/8403917 · Cited by 1
“Currently, studies have shown that the incidence of hypoglycemic events in DKD patients during the use of intensive glycemic control measures is about 20%–40% [16–18].”
Betônico, C. D. C. R. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-05042017-153224 · Cited by 1
Инсулин гларгин: фармакокинетические и фармакодинамические основы клинического эффекта
Klimontov, V. V., & Myakina, N. E. (2014) · doi:10.14341/dm6691-4788
Insulin Pump Therapy in Non-Pregnant Hospitalized Adults: A Review of the Literature
Gibson, J. M. (2014) · Journal of Nursing & Care · doi:10.4172/2167-1168.1000199
“Weight-Based Total Daily Dose (TDD) Insulin Calculation [42]”
BackgroundManagement of Diabetes in the Hospital
Korytkowski, M. T. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch17
Kattan, W. (2017) · STARS (University of Central Florida)
Principles of Care in the Diabetic Surgical Patient
Khazai, N. B., & Hamdy, O. (2018) · Contemporary diabetes · doi:10.1007/978-3-319-89869-8_6
Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes
Hahr, A. J., & Molitch, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_23
Self-citationDiabetes Management in the Elderly Patient with Kidney Disease
Molitch, M. E. (2015) · Cited by 2
Self-citationHahr, A. J., & Molitch, M. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_16
Self-citationMicrovascular complications: Diabetic kidney disease
Memon, R. A., & Syed, F. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00002-4
Current Standards of Care for Inpatient Type 2 Diabetes Mellitus
Friedman, N., & Lee, H. J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_2 · Cited by 1
Self-citationHaak, T., Fritsche, A., Füchtenbusch, M., Gehr, B., Gölz, S., Kröger, J., Siegmund, T., Ziegler, R., Droßel, D., Fuchs, S., et al. (2025) · Die Diabetologie · doi:10.1007/s11428-024-01280-z
Metadata
- Authors
- Baldwin, D., Zander, J., Munoz, C., Raghu, P., DeLange-Hudec, S., Lee, H., Emanuele, M. A., Glossop, V., Smallwood, K., & Molitch, M.
- Affiliations
- Rush University (US)
- Division of Endocrinology, Loyola University, Maywood, Illinois
- Loyola University Chicago (US)
- Northwestern University (US)
- Corresponding author
- Baldwin, David
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-09-11
- Volume
- 35
- Issue
- 10
- Pages
- 1970-1974
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3447835
- OpenAlex
- W2102487071
- Cited by
- 103
- References
- 26
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 3 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 16 · 2014: 10 · 2013: 8 · 2012: 4
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- insulin glargine, insulin glulisine, type 2 diabetes, renal failure, hypoglycemia, hyperglycemia management, hospitalized patients, glomerular filtration rate, insulin dose adjustment
- MeSH terms
- Insulin Glargine, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Hyperglycemia, Hypoglycemia, Insulin, Male, Middle Aged, Treatment Outcome, Insulin, Long-Acting, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.